Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Naim Alkhouri

Showing results (1-10 of 306) with videos related to

Pageof 31
Sort By:
Expert Opinion on Investigational Drugs|January 24, 2020
Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): prevalence, therapeutic innovations, and stumbling blocks for clinical developmentNaim Alkhouri
Gastroenterology & Hepatology|April 25, 2022
Drug Development for the Management of Nonalcoholic Steatohepatitis CirrhosisNaim Alkhouri
The Journal of Pediatrics|April 9, 2015
The use of omega-3 Fatty acids in nonalcoholic Fatty liver disease: the end of the road or a new beginning?Naim Alkhouri
Gastroenterology & Hepatology|March 21, 2025
Recent Data From the ESSENCE Trial on Semaglutide in Metabolic Dysfunction-Associated SteatohepatitisNaim Alkhouri
Expert Opinion on Investigational Drugs|January 28, 2020
NASH and NAFLD: emerging drugs, therapeutic targets and translational and clinical challengesNaim Alkhouri
Clinical Liver Disease|April 18, 2019
Putting it all together: Noninvasive diagnosis of fibrosis in nonalcoholic fatty liver disease in adults and childrenNaim Alkhouri
Expert Opinion on Investigational Drugs|December 24, 2019
Thyromimetics as emerging therapeutic agents for nonalcoholic steatohepatitis: rationale for the development of resmetirom (MGL-3196)Naim Alkhouri
Clinical Liver Disease|February 15, 2019
An Update on the Pharmacological Treatment of Nonalcoholic Fatty Liver Disease: Beyond Lifestyle ModificationsNaim Alkhouri, Andrea Scott
The American Journal of Managed Care|November 8, 2024
Management strategies for metabolic dysfunction-associated steatotic liver disease (MASLD)Naim Alkhouri, Mazen Noureddin
Hepatology (Baltimore, Md.)|November 8, 2023
Letter to the Editor: Comparing quantitative MRI technologies in steatotic liver diseaseNaim Alkhouri, Mukesh Harisinghani
Pageof 31

Showing results (1-10 of 306) with videos related to

Sort By:
Pageof 31
Expert Opinion on Investigational Drugs|January 24, 2020
Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): prevalence, therapeutic innovations, and stumbling blocks for clinical developmentNaim Alkhouri
Gastroenterology & Hepatology|April 25, 2022
Drug Development for the Management of Nonalcoholic Steatohepatitis CirrhosisNaim Alkhouri
The Journal of Pediatrics|April 9, 2015
The use of omega-3 Fatty acids in nonalcoholic Fatty liver disease: the end of the road or a new beginning?Naim Alkhouri
Gastroenterology & Hepatology|March 21, 2025
Recent Data From the ESSENCE Trial on Semaglutide in Metabolic Dysfunction-Associated SteatohepatitisNaim Alkhouri
Expert Opinion on Investigational Drugs|January 28, 2020
NASH and NAFLD: emerging drugs, therapeutic targets and translational and clinical challengesNaim Alkhouri
Clinical Liver Disease|April 18, 2019
Putting it all together: Noninvasive diagnosis of fibrosis in nonalcoholic fatty liver disease in adults and childrenNaim Alkhouri
Expert Opinion on Investigational Drugs|December 24, 2019
Thyromimetics as emerging therapeutic agents for nonalcoholic steatohepatitis: rationale for the development of resmetirom (MGL-3196)Naim Alkhouri
Clinical Liver Disease|February 15, 2019
An Update on the Pharmacological Treatment of Nonalcoholic Fatty Liver Disease: Beyond Lifestyle ModificationsNaim Alkhouri, Andrea Scott
The American Journal of Managed Care|November 8, 2024
Management strategies for metabolic dysfunction-associated steatotic liver disease (MASLD)Naim Alkhouri, Mazen Noureddin
Hepatology (Baltimore, Md.)|November 8, 2023
Letter to the Editor: Comparing quantitative MRI technologies in steatotic liver diseaseNaim Alkhouri, Mukesh Harisinghani
Pageof 31